Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033788369> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W3033788369 abstract "Abstract Background and Aims Patient with type 2 diabetes mellitus (T2DM) included in trials of sodium-glucose cotransporter 2 inhibitors are heterogeneous in terms of disease severity. We assessed the effects of canagliflozin compared to placebo on cardiovascular and renal outcomes in the CANVAS program according to severity of T2DM as indicated by intensity of treatment, duration of diabetes and glycaemic control. Method We compared effects on major adverse cardiovascular events ([MACE], defined as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) according to three indicators of T2DM severity at study baseline: number of oral glucose lowering treatments or insulin therapy (0-1, 2, 3+, insulin), duration of diabetes (<10, 10-16, >16 years) and HbA1c (<7.0, 7.0-7.5, 7.5-8.0, 8.0-8.5, 8.5-9, >9.0%). We also assessed effects on other pre-specified cardiovascular outcomes, and an adjudicated composite of end-stage kidney disease, renal death or sustained 40% decline in estimated glomerular filtration rate. We assessed for constancy of hazard ratios across subgroups by fitting an interaction term that tested for linear trend. Results Of 10,142 participants in the CANVAS Program, 1011 experienced a MACE during a mean follow-up of 3.6 years. Event rates for MACE were higher in those with longer duration of diabetes and higher HbA1c at baseline. The effect of canagliflozin on MACE in the overall population (HR 0.86, 95 % CI 0.75-0.97) was consistent irrespective of the number of glucose lowering treatments (p=0.509), duration of diabetes (p=0.174) and baseline HbA1c (p =0.314). Effects were also consistent across different levels of T2DM disease severity for all other outcomes studied. Conclusion Higher event rates were observed in those with longer disease duration and higher HbA1c. The proportional risk reductions achieved with canagliflozin were comparable regardless of diabetes duration, number of therapies or HbA1C at baseline." @default.
- W3033788369 created "2020-06-12" @default.
- W3033788369 creator A5015488634 @default.
- W3033788369 creator A5019179564 @default.
- W3033788369 creator A5027520502 @default.
- W3033788369 creator A5033053622 @default.
- W3033788369 creator A5033623434 @default.
- W3033788369 creator A5039186899 @default.
- W3033788369 creator A5039432822 @default.
- W3033788369 creator A5040550338 @default.
- W3033788369 creator A5045497276 @default.
- W3033788369 creator A5056130529 @default.
- W3033788369 creator A5060865001 @default.
- W3033788369 creator A5061838242 @default.
- W3033788369 creator A5075162144 @default.
- W3033788369 creator A5087474773 @default.
- W3033788369 date "2020-06-01" @default.
- W3033788369 modified "2023-09-27" @default.
- W3033788369 title "P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM" @default.
- W3033788369 doi "https://doi.org/10.1093/ndt/gfaa142.p1028" @default.
- W3033788369 hasPublicationYear "2020" @default.
- W3033788369 type Work @default.
- W3033788369 sameAs 3033788369 @default.
- W3033788369 citedByCount "0" @default.
- W3033788369 crossrefType "journal-article" @default.
- W3033788369 hasAuthorship W3033788369A5015488634 @default.
- W3033788369 hasAuthorship W3033788369A5019179564 @default.
- W3033788369 hasAuthorship W3033788369A5027520502 @default.
- W3033788369 hasAuthorship W3033788369A5033053622 @default.
- W3033788369 hasAuthorship W3033788369A5033623434 @default.
- W3033788369 hasAuthorship W3033788369A5039186899 @default.
- W3033788369 hasAuthorship W3033788369A5039432822 @default.
- W3033788369 hasAuthorship W3033788369A5040550338 @default.
- W3033788369 hasAuthorship W3033788369A5045497276 @default.
- W3033788369 hasAuthorship W3033788369A5056130529 @default.
- W3033788369 hasAuthorship W3033788369A5060865001 @default.
- W3033788369 hasAuthorship W3033788369A5061838242 @default.
- W3033788369 hasAuthorship W3033788369A5075162144 @default.
- W3033788369 hasAuthorship W3033788369A5087474773 @default.
- W3033788369 hasBestOaLocation W30337883691 @default.
- W3033788369 hasConcept C126322002 @default.
- W3033788369 hasConcept C127413603 @default.
- W3033788369 hasConcept C134018914 @default.
- W3033788369 hasConcept C159641895 @default.
- W3033788369 hasConcept C207103383 @default.
- W3033788369 hasConcept C2777180221 @default.
- W3033788369 hasConcept C2777451236 @default.
- W3033788369 hasConcept C2778653478 @default.
- W3033788369 hasConcept C2780645631 @default.
- W3033788369 hasConcept C2780739214 @default.
- W3033788369 hasConcept C2908647359 @default.
- W3033788369 hasConcept C2910068830 @default.
- W3033788369 hasConcept C44249647 @default.
- W3033788369 hasConcept C45393284 @default.
- W3033788369 hasConcept C500558357 @default.
- W3033788369 hasConcept C555293320 @default.
- W3033788369 hasConcept C71924100 @default.
- W3033788369 hasConcept C78519656 @default.
- W3033788369 hasConcept C99454951 @default.
- W3033788369 hasConceptScore W3033788369C126322002 @default.
- W3033788369 hasConceptScore W3033788369C127413603 @default.
- W3033788369 hasConceptScore W3033788369C134018914 @default.
- W3033788369 hasConceptScore W3033788369C159641895 @default.
- W3033788369 hasConceptScore W3033788369C207103383 @default.
- W3033788369 hasConceptScore W3033788369C2777180221 @default.
- W3033788369 hasConceptScore W3033788369C2777451236 @default.
- W3033788369 hasConceptScore W3033788369C2778653478 @default.
- W3033788369 hasConceptScore W3033788369C2780645631 @default.
- W3033788369 hasConceptScore W3033788369C2780739214 @default.
- W3033788369 hasConceptScore W3033788369C2908647359 @default.
- W3033788369 hasConceptScore W3033788369C2910068830 @default.
- W3033788369 hasConceptScore W3033788369C44249647 @default.
- W3033788369 hasConceptScore W3033788369C45393284 @default.
- W3033788369 hasConceptScore W3033788369C500558357 @default.
- W3033788369 hasConceptScore W3033788369C555293320 @default.
- W3033788369 hasConceptScore W3033788369C71924100 @default.
- W3033788369 hasConceptScore W3033788369C78519656 @default.
- W3033788369 hasConceptScore W3033788369C99454951 @default.
- W3033788369 hasLocation W30337883691 @default.
- W3033788369 hasOpenAccess W3033788369 @default.
- W3033788369 hasPrimaryLocation W30337883691 @default.
- W3033788369 hasRelatedWork W10870039 @default.
- W3033788369 hasRelatedWork W11119028 @default.
- W3033788369 hasRelatedWork W11793912 @default.
- W3033788369 hasRelatedWork W16668515 @default.
- W3033788369 hasRelatedWork W17661181 @default.
- W3033788369 hasRelatedWork W634034 @default.
- W3033788369 hasRelatedWork W7071295 @default.
- W3033788369 hasRelatedWork W7858436 @default.
- W3033788369 hasRelatedWork W8252164 @default.
- W3033788369 hasRelatedWork W9192601 @default.
- W3033788369 isParatext "false" @default.
- W3033788369 isRetracted "false" @default.
- W3033788369 magId "3033788369" @default.
- W3033788369 workType "article" @default.